Valuation
- Market cap
- 405,512,000
- Revenue TTM
- $1,380,000
- Net income TTM
- $-83,780,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -6,071.01%
- Debt to equity
- 0.00
Trading
- Volume
- 1,867,600
- Avg volume
- 3,407,590
- Day's range
- $0.24 – $0.26
- Shares out
- 1,590,242,000
- Stochastic %K
- 28%
- Beta
- -0.86
- Analysts
- Strong Buy
- Price target
- $2.00
Company profile
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addit...
Show more
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 240 497 9024
- Website
- https://www.nwbio.com
- Address
- 4800 Montgomery Lane, Suite 800, Bethesda, United States
Latest news
No headlines yet.
